Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (431)	8/30/1999 9:35:00 AM
From: NeuroInvestment	Respond to of 626

The NI review of Titan in October 98 said that the royalties to Titan, net after payments to Hoechst, would be in the "10% range". I would have to check my notes to see if I have information about Hoechst's share, it's irrelevant, I care only about Titan's share. Titan is not allowed by Novartis to disclose the precise number, which may include some variance depending on sales level, but this is a reliable estimate (i.e. perhaps there is a range of 9-11%) NeuroInvestment (www.neuroinvestment.com)